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Abstract
Background: Arachidonate metabolites are important regulators of human breast cancer cells.
Production of bioactive lipids are frequently initiated by the enzyme phospholipase A2 which
releases arachidonic acid (AA) that is rapidly metabolized by cyclooxygenases (COX) or
lipoxygenases (LO) to other highly potent lipids.
Methods: In this study we screened a number of inhibitors which blocked specific pathways of AA
metabolism for their antiproliferative activity on MCF-7 wild type and MCF-7 ADR drug resistant
breast cancer cells. The toxicity of these inhibitors was further tested on human bone marrow cell
proliferation.
Results: Inhibitors of LO pathways (specifically the 5-LO pathway) were most effective in blocking
proliferation. Inhibitors of platelet activating factor, a byproduct of arachidonate release, were also
effective antiproliferative agents. Curcumin, an inhibitor of both COX and LO pathways of
eicosanoid metabolism, was 12-fold more effective in blocking proliferation of the MCF-7 ADRs
cells compared to MCF-7 wild type (WT) cells. These inhibitors that effectively blocked the
proliferation of breast cancer cells showed varying degrees of toxicity to cultures of human bone
marrow cells. We observed greater toxicity to bone marrow cells with inhibitors that interfere
with the utilization of AA in contrast to those which block utilization of its downstream
metabolites. MK-591, MK-886, PCA-4248, and AA-861 blocked proliferation of breast cancer cells
but showed no toxicity to bone marrow cells.
Conclusion: These inhibitors were effective in blocking the proliferation of breast cancer cells and
may be potentially useful in human breast cancer therapy.
Background
Epidemiologic investigations have suggested an associa-
tion of dietary fat intake with breast cancer risk. Bioactive
lipids generated from these fat metabolites are known to
increase proliferation in cancer cells. Various studies have
suggested dietary fat content, especially polyunsaturated
fatty acids, promotes tumor growth by increasing synthe-
sis of eicosanoids, particularly arachidonic acid (AA)
products [1-4]. The possible role of AA derived eicosa-
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noids as regulators of neoplastic cell growth is an area of
significant interest in breast cancer biology.
Phospholipase A2 (PLA2) is the family of enzymes, which
specifically hydrolyzes the 2-acyl position of glycerophos-
pholipid. It has been reported that the concentration of
PLA2 was elevated in the lungs, breasts, and the digestive
organs of patients with malignant tumors and that the
incidence and magnitude of the elevation increased with
advanced cancer stage [5,6]. In our previous work with
wild type (WT) and drug-resistant (MCF-7 ADR) MCF-7
cells, we observed PLA2 activity with specificity toward
either linoleoyl or arachidonyl phosphatidylinositol [7].
PLA2's are usually most efficient with polyunsaturated
fatty acids in the SN-2 position, which result in the release
of AA [7]. AA is metabolized through the cyclooxygenase
pathway, which results in prostaglandin production or
through the 5-lipoxygenase (5-LO) pathway, which
results in the production of leukotriene [8]. Both prostag-
landins and leukotrienes directly stimulate the growth of
malignant cells [9-11].
Metabolism of exogenous AA by lipoxygenase or cycloox-
ygenase pathways produces a myriad of highly potent bio-
active lipids which include leukotrienes, HPETEs, HETEs,
and prostaglandins. Many of these metabolites have been
shown to play a significant role in cancer cell growth. The
arachidonate-derived eicosanoids PGE2, LTB4, and 5-, 12-
, and 15-HETEs have been shown to be significantly
higher in human breast cancer cells than control cells
[12]. In Swiss 3T3 cells, stimulation of DNA synthesis
occurs predominantly by activation of arachidonic acid
release, followed by its oxidation to PGE2 and stimula-
tion of adenylyl cyclase [13]. Metabolites of arachidonic
acid and linoleic acid served as regulators of the EGF
transduction system in Syrian hamster embryo fibroblasts
[14,15]. Initiation of growth of human myeloblastic
leukemia cells is dependent upon the increased formation
of AA and its derivatives, formed primarily via the lipoxy-
genase pathway and the initiation of growth in these cells
was followed by the rapid release of AA, HETEs and phos-
pholipids into the culture medium [16]. The inhibitors of
lipoxygenase and cyclooxygenase metabolism were
shown to block proliferation in a human gastric cell line
derived from a stomach tumor [17,18]. The consequent
alteration in PKC, catalyzed by phospholipase(s) activity
in endothelial cells, regulates the growth-dependent
changes in AA release [19].
Avis et al. reported that exogenous addition of 5-HETE
was found to stimulate lung cancer growth in vitro [20].
When selective antagonists were used to inhibit 5-lipoxy-
genase metabolism, significant growth reduction resulted
in a number of lung cancer cell lines. Similarly, LTB4 and
12(R)-HETE significantly increased proliferation of two
colon carcinoma cell lines, HT-29 and HCT-15 [10]. How-
ever, isomers of these two compounds such as LTB5 and
12(S)-HETE failed to affect the proliferation rate of these
two cell lines. This demonstrates the importance of specif-
icity in cancer cell proliferation. Epidemiological studies
show that death rates from colon cancer decreased 40%
for individuals who took aspirin (AA inhibitor) more than
16 times/month [21]. The use of inhibitors to manipulate
AA pathways will help us better understand the function
of elevated PLA2 levels in cancer cells, which may lead to
the discovery of new anti-cancer drugs.
In the present study we have examined the effect of vari-
ous inhibitors of arachidonic acid signaling pathways on
growth of breast cancer cells, especially the drug resistant
ones. It has been a challenge to treat drug resistant cancer
patients effectively that have less toxicity. We show that
inhibitors of the 5-LO pathway can block growth of breast
cancer cells, especially the drug resistant MCF-7 ADR line
very effectively. The toxicity of these inhibitors was then
tested on the growth of bone marrow cells. The selection
of some of these inhibitors might be an alternative treat-
ment regimen for the breast cancer patients especially
those that develop drug resistance during their course of
treatment.
Methods
Materials
MK-591 was a gift from Merck-Frost, Pointe Claire, Que-
bec, Canada. All other inhibitors were purchased from
BIOMOL Research Laboratories, Inc. The lipoxygenase
inhibition assay was obtained from Cayman Chemical
Company (Ann Arbor, MI).
Cells
The human breast cancer MCF-7 Wild Type (WT) and its
Adriamycin-Resistant, (MCF-7 ADR) cells were obtained
from Kenneth Cowan (NCI, NIH Bethesda, MD), in
accordance with the WRAIR human use protocol for
established breast cancer cells. The cells were grown in
Improved Modified Essential Medium (IMEM) contain-
ing 8% fetal bovine serum, 50,000 units/liter penicillin
and 5,000 μg/l streptomycin at 37°C with 5% CO2.
Human bone marrow mononuclear cells were obtained
from healthy volunteer donors arranged by Poietic Tech-
nologies Inc. (Gaithersburg, MD) and used for colony
assays without any prior treatment. The stromal colonies
were grown in IMDM-based Long Term Culture Media
(LTCM) containing 25% horse serum (Hyclone) with 5%
CO2 and 100% humidity at 37°C.
Methyl (3H)-thymidine incorporation
Inhibition of proliferation in MCF-7 WT or MCF-7 ADR
cultures was performed in 96-well plates. Cells wereBMC Cancer 2007, 7:138 http://www.biomedcentral.com/1471-2407/7/138
Page 3 of 9
(page number not for citation purposes)
plated 15,000 cells/well in 0.2 ml IMEM culture fluid1 and
incubated overnight in triplicate. Inhibitors were added
(50 μl) to achieve the indicated concentration and incu-
bated for three days. During the last 18 hours,
Methyl(3H)-thymidine (1 μCi/well) was added. The cells
were trypsinized and harvested using Packard Unifilter
System. The filter plates were dried in the air. Then, 40 μL
of Packard Microscint 0 scintillation cocktail was added to
each well and the filter plates were counted using Packard
Top-count.
Use of inhibitors in cell culture: The inhibitors were dis-
solved in the appropriate solvents namely DMSO or etha-
nol as recommended by the manufacturer for each
compound. The stock solutions of these compounds were
at 100 mM for NDGA, MK886, MK591, PCA-4248, and at
200 mM for curcumin, AA881 and ketoconazole. Stock
solutions were then diluted in the cell culture media to
obtain the final concentration for each compound. Simi-
lar amounts of the appropriate solvent were added to the
control cells.
Lipoxygenase inhibition assay
Measurements of the lipoxygenase enzyme activity were
carried out using a lipoxygenase inhibition assay kit.
MCF-7 breast cancer cells were treated with each of the
inhibitors at 20 μM concentrations. Each treatment was
carried out in triplicate. Cells were lysed using a lysis
buffer and the lipoxygenase activity was determined in the
control and treated cells using the lipoxygenase assay kit
obtained from Cayman Co (Ann Arbor, MI). Each assay
was carried out in triplicate using the plate provided by
the kit as instructed by the manufacturer. Cells lysates
from control and treated cells were added to the plate fol-
lowed by the substrate (linoleic acid) and then the chro-
mogen. Absorbance intensities were determined at 500
nm using a plate reader.
Colony Assay
Human bone marrow stroma colony studies were per-
formed using human bone marrow mononuclear cells2.
Cells (2 × 105 cells/well) were plated in 4-well plates with
5 ml LTCM and inhibitors were added on the second day.
The media was changed with fresh media either with
(continuous treatment) or without drugs (pulse) every
week. The stroma colonies were stained on the second and
fourth week of treatment with HEMA 3 (differential
hematology stain, CMS). Colonies with diameters larger
than 1 mm were counted and the size of the each colony
was measured.
The hematopoietic progenitor colony assay was per-
formed using Methylcellulose-based Colony Cocktail
from Stem Cell Technologies, Inc. (HCC-4434) contain-
ing 30% Fetal Bovine Serum; 50 ng/ml rh Stem Cell Fac-
tor; 10 ng/ml rh GM-CSF; 10 ng/ml rh IL-3; and 3 units/
ml rh Erythropoietin. Inhibitors were premixed with the
cocktail (4.5 ml) and were added with the cells and plated
in a 35 mm diameter gridded tissue culture plate (Nunc.
Inc.). After a two week incubation period, the hematopoi-
etic colonies were counted using an inverted phase micro-
scope with 40× magnification. Using the standard criteria
developed by Stem Cell Technologies Inc. (Atlas of
Human Hematopoietic Colonies), the colonies were clas-
sified into categories that included: CFU-GM, BFU-E,
CFU-E, CFU-Mix, and CFU-GEMM.
Both stroma colony and hematopoietic colony assay
experiments were performed with four replicates and
repeated at least three times with different lots of cells.
Regardless of the lot of the cells, the same trends were
observed.
Hoechst staining
MCF-7 WT cells were plated overnight on an eight well
chamber slide, pretreated with 20 μM MK886, Curcumin
or NDGA and incubated for 48 hours. The cells were then
fixed with paraformaldehyde and stained with 10 μM
HOECHST 33258 dye for 30 minutes. Cells with bright,
fragmented, condensed nuclei were identified as apop-
totic cells.
Statistical analysis
All experiments were performed as a replicate of three
treatments and each assay was performed three independ-
ent times. Data were analyzed using analysis of variance
(ANOVA). Student's t tests were used to determine the sig-
nificance between mean group values compared to the
control. A P value of < 0.05 was considered statistically
significant. The standard deviation was calculated for each
assay at each time point of the assay. Data were expressed
as means ± S.D.
Results
Effect of Lipoxygenase/Cyclooxygenase inhibitors on 
breast cancer cell growth: and apoptosis
Cells were plated in 96 well plates in the presence of vari-
ous inhibitors of the arachidonic acid pathway and their
growth was measured by 3H Thymidine incorporation.
Inhibition of proliferation in MCF-7 WT or MCF-7 ADR
cultures with lipoxygenase inhibitors is shown in figure 1.
Inhibitors of lipoxygenase (LO) pathways were most
effective at blocking proliferation. The effect of MK591,
MK886 and NDGA was compared between the MCF-WT
(Fig 1A) and MCF-7 ADR cells (Fig 1B). In the presence of
these inhibitors, a concentration-dependent decrease in
growth of these cells was observed. Curcumin, AA861,
and ketoconazole also blocked growth of these breast can-
cer cells (Fig. 1C, D). Curcumin, a dual inhibitor of 5-
lipoxygenase and cyclooxygenase and an agent with anti-BMC Cancer 2007, 7:138 http://www.biomedcentral.com/1471-2407/7/138
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inflammatory and anti-oxidant properties [22], was much
more effective (ca. 11 fold) at blocking proliferation of the
multi drug-resistant cells, MCF-7 ADR compared to MCF-
7 wild type (WT) cells. It showed maximum inhibition of
growth of breast cancer cells at very low concentrations.
Since metabolites of 5-LO have properties of a co-growth
factor, it is possible that decreases in 5-LO products
inhibit breast cancer cell proliferation. It is also possible
that decreases in the ratio of lipoxygenase to cyclooxygen-
ase products are responsible for the inhibition.
We studied the effect of curcumin, NDGA or MK886 on
apoptosis in MCF-7 cells using the Hoechst staining
method. As shown in figure 2, curcumin was the most
effective in inducing apoptosis in these breast cancer cells
after 24 hr.
Effect of the inhibitors of the activity of 5-LO in MCF-7 
cells
The lipoxygenase activity was studied using the Cayman
lipoxygenase inhibitor screening assay that measures the
hydroperoxides produced in the lipoxygenation reaction.
MCF-7 WT Cells were treated with MK886, NDGA or Cur-
cumin and the enzyme activity was determined in the con-
trol and inhibitor treated cells. As shown in figure 3, these
compounds effectively inhibited the activity of 5-LO in
MCF-7 cells. This correlates with the findings by Avis et al
that showed that these inhibitors inhibited the activity of
5-LO in MCF-7 breast cancer cells [23].
Inhibition of proliferation in (A and C) MCF-7 WT or (B and D) MCF-7 ADR cultures with lipoxygenase inhibitors; MK59I,  MK886, NDGA for A and B; curcumin, ketoconazole, and AA88I for C and D Figure 1
Inhibition of proliferation in (A and C) MCF-7 WT or (B and D) MCF-7 ADR cultures with lipoxygenase inhibitors; MK59I, 
MK886, NDGA for A and B; curcumin, ketoconazole, and AA88I for C and D. Cells were plated in IMEM culture fluid contain-
ing 8% FBS, 0.5% penicillin and streptomycin sulfate,0.5% kanamycin sulfate, and 1% MEM Vitamin Solution. Inhibitors were 
added after 24 hours and the cells were incubated in a humidified chamber of 5% CQ2 for an additional 48 hours. Thymidine 
was incorporated 16 hours prior to harvest and the cells were harvested using Packard Unifilter System. Values are expressed 
as % of the control. Data points represent the mean ± SD of three experiments with samples run in replicates of six.BMC Cancer 2007, 7:138 http://www.biomedcentral.com/1471-2407/7/138
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Regulation of breast cancer cell growth by PAF inhibitors
PCA-4248 inhibits PAF (a byproduct released from ara-
chidonate metabolism) binding to human platelet and
PMNL receptors. Inhibition of proliferation in MCF-7 WT
or MCF-7 ADR cultures with PCA-4248 is shown in Figure
4. Blocking PAF binding results in the accumulation of
arachidonate metabolism products, which may account
for the inhibition of proliferation in MCF-7 WT or MCF-7
ADR cultures by PCA-4248.
Human Bone Marrow progenitor colonies in the presence 
of inhibitors
For any drug to be useful for chemotherapy it is important
to study the toxicity of the drugs on bone marrow cells. To
determine the toxicity of these inhibitors, the ability of
human bone marrow cells to form colonies was studied.
Human bone marrow stroma colonies with one week of
treatment with the inhibitors are shown in Figure 5 (two
week colonies). When compared to the control values,
neither the total number of stroma colonies, the average
area of each colony, nor the percentage coverage of the
plate changed in the presence of MK-591, MK-886, and
PCA-4248 at IC50. However, the stroma colonies were
wiped out even with concentrations of the inhibitors
lower than IC50 for NDGA. Lipoxygenase inhibitors (MK-
591 and MK-886) did not have any toxic effect on the for-
mation of stroma colonies. However, PAF Binding Inhib-
itor PCA-4248, did not affect the growth of stroma
colonies when the concentration was at IC90. When the
human bone marrow cells were treated for two weeks or
four weeks continuously with the inhibitors, the growth
of the colonies show similar trends to those treated for
one week (Figure 6).
Figure 7 shows the distribution of hematopoietic colonies
categorized as BFU-E, CFU-E, CFU-GM, CFU-mix and
CFU-GEMM in the presence of these inhibitors. Again
MK-591, MK-886, and PCA-4248 showed no toxicity on
the hematopoietic colonies since the relative population
of the hematopoietic colonies in these treated samples
was similar to the control. NDGA was toxic to hematopoi-
etic colonies only at higher concentrations. Thus the MK
drugs and PCA are some of the drugs that may have some
use in the clinics in future because they are safe and effec-
tive in blocking the growth of breast cancer cells.
Effect of the inhibitor on the activity of 5-LO in MCF-7 Figure 3
Effect of the inhibitor on the activity of 5-LO in MCF-
7: Cells were treated with each inhibitor and the lipoxygen-
ase activity was determined in treated and control cells. Data 
points represent the mean ± SD of three experiments with 
samples run in triplicate.
Induction of apoptosis in MCF-7 WT cells with (B) Curcu- min, (C) NDGA and (D) MK 886 Figure 2
Induction of apoptosis in MCF-7 WT cells with (B) Curcu-
min, (C) NDGA and (D) MK 886. MCF-7 WT cells were 
plated in Labtek 8 chamber glass slides for 24 hours and then 
incubated with the inhibitors for 48 hours. Cells were fixed 
using paraformaldehyde and stained with HOECHST 33258 
dye for 30 minutes. Cells with bright, fragmented, condensed 
nuclei were identified as apoptotic cells.
A                                               B
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Discussion
There is a constant need for additional therapeutic strate-
gies to combat the disease in order to improve the quality
of life and prolong survival for women with breast cancer.
Bioactive lipids play an important role in the growth and
development of the normal mammary gland. Under-
standing the regulatory role of these lipids on the control
of the epithelial cell population is extremely important.
Dietary fat content, especially polyunsaturated fatty acids,
promotes tumor growth by increasing synthesis of eicosa-
noids particularly AA products [24]. The possible role of
arachidonic acid derived eicosanoids as regulators of neo-
plastic cell growth is an area of significant interest in
breast cancer biology.
Signal transduction explains the molecular events by
which extracellular signals elicits an intracellular
response. The generation of a variety of lipid signal trans-
duction molecules from hydrolysis of membrane phos-
pholipids is an early response. Several types of signal
transduction pathway inhibitors effectively blocked pro-
liferation in MCF-7 WT or MCF-7 ADR cultures. Lipoxyge-
nase (LO) inhibitors NDGA, MK591, AA-861 and MK886
were equally effective at blocking proliferation for MCF-7
WT and MCF-7 ADR cells. We confirmed the inhibition of
5-LO enzyme activity in MCF-7 by the inhibitors tested at
the concentrations used in the proliferation assays.
Curcumin has been shown to strongly inhibit the LO
pathway and weakly inhibit the COX pathway. Curcumin
inhibits proliferation by blocking the action of the Thymi-
dine kinase enzyme that is necessary for cell cycle progres-
sion through the S-phase [25]. In immortalized NIH 3T3
and malignant cancer cell lines, Curcumin induced cell
shrinkage, chromatin condensation, DNA fragmentation,
and characteristics of apoptosis. In the present study, it
inhibits the proliferation for both MCF-7 WT and MCF-7
ADR cells. However, the IC50 for MCF-7 ADR cells (12
μM) is much smaller than that for MCF-7 WT cells (90
μM). Interestingly, Curcumin effectively blocked prolifer-
ation in only MCF-7 ADR much more than in MCF-7 WT
cells. However Ketoconazole was more effective with
MCF-7 WT cells than MCF-7 ADR cells.
The cyclooxygenase (COX) enzyme is an important
enzyme because it catalyzes the initial reaction of ara-
chidonate metabolism that leads to the formation of pros-
taglandins, thromboxane, and prostacyclin. Recently, a
second form of the cyclooxygenase (COX) enzyme, COX-
2, has been isolated. A single amino acid difference in the
active site (valine 509 to isoleucine) and a series of differ-
ences in the active site confers selectivity for COX-2. COX-
2, which can be induced by cytokines and growth factors,
is linked to inflammatory cell types and tissues whereas
COX-1's course of action resides primarily in the stomach
and kidney [26,27]. It is possible that a selective COX-2
inhibitor may eliminate the side effects associated with
COX-1 while still maintaining COX-2 inhibition and vice
versa. Teh at al. has reported that Cox-2 inhibitors
induced apoptosis and inhibited proliferation in MCF-7
cells [35].
An inhibitor of PAF (PCA-4248) effectively blocked pro-
liferation of MCF-7 WT and MCF-7 ADR. Inhibitors of the
LO pathway or specifically the 5-LO pathway were most
effective at blocking proliferation. Blocking both LO and
COX pathways in WT cells using Curcumin also inhibits
proliferation. We have previously observed that AA
metabolism in the presence of aspirin was shifted to large
increases in LO products [20]. This might have occurred in
the presence of these dual inhibitors, which could explain
their lack of inhibitory activity.
Inhibition of proliferation in MCF-7 WT and MCF-7 ADR  cultures with PAP binding inhibitors (A) PCA-4248 and (B)  Thapsigargin Figure 4
Inhibition of proliferation in MCF-7 WT and MCF-7 ADR 
cultures with PAP binding inhibitors (A) PCA-4248 and (B) 
Thapsigargin. Cells were harvested with the same procedure 
used in figure 2. Values are expressed as % of the control. 
Data points represent the mean ± SD of three independent 
experiments with samples run in replicates of six.BMC Cancer 2007, 7:138 http://www.biomedcentral.com/1471-2407/7/138
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Human bone marrow stroma colonies treated with inhibitors for the first week and fresh media for the second week Figure 5
Human bone marrow stroma colonies treated with inhibitors for the first week and fresh media for the second week. (A) The 
number of colonies, (B) average area of the colonies, (C) and the percentage of coverage of the colonies are shown. The cor-
responding concentration of inhibitors were added to the cells which were plated in IMDM-based Long Term Culture Media 
containing 25% horse serum and incubated in a humidified chamber containing 5% CQ2. Data points represent the mean ± SD 
of three experiments.
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NDGA, MK-591, and MK-886 blocked arachidonic acid
metabolism pathway at different stages and all effectively
inhibit the proliferation of MCF-7 WT and MCF-7 ADR
cultures. MK-591 and MK-886 did not exhibit any toxicity
on either human bone marrow stroma colonies or on
human hematopoietic colonies at a concentration lower
than IC90. However, NDGA completely blocked stroma
colony formation even though the hematopoietic colo-
nies still survived at a concentration lower than IC70. This
could be due to the fact that it blocks the initial conver-
sion from AA to any/all of the lipoxygenases and their
products. PCA-4248, an inhibitor of PAF, did not have an
effect on either stroma colonies or hematopoietic colonies
at a concentration below IC90. Our results indicate that
MK-591, MK-886, and PCA-4248 could be good candi-
dates for medical clinical trials.
Conclusion
Use of these inhibitors of different signaling pathways
gives us a better understanding of the mechanism of
action of the bioactive lipids in breast cancer. By blocking
one of these pathways we were able to block the growth of
breast cancer cells, especially the cells that develop drug
resistance. However not all of these inhibitors serve as a
potential therapeutic agents because of their toxicity to the
bone marrow cells. The MK drugs, which block 5-LO path-
way and block cell growth, were not toxic to the bone mar-
row cells and therefore may be of some use in controlling
the growth of breast cancer cells opening new avenues for
therapeutic intervention.
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